NCT02222545Phase 2Completed

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2020-01-30Actual

Enrollment · participants58Actual

Source updated2024-08-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Thrombotic Microangiopathies

Treatments or interventions studied

OMS721Biological

Primary outcomes · main study measures

Read the study measures

measure: Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA; description: Incidence of treatment-emergent adverse events (AEs): clinically significant changes in vital signs, ECG, and laboratory tests were reported as AEs.; timeFrame: Day 1 to 37 days after end of treatment, approximately up to 31 weeks.; measure: Number of Participants With HSCT-TMA Who Respond to OMS721; description: Response defined as: Improvement in TMA laboratory markers of platelet count and lactate dehydrogenase (LDH) and improvement in clinical status; timeFrame: Day 1 to up to 2 years following the first dose of OMS721

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history